Amarantus BioSciences’ CEO Gerald Commissiong to Appear on the Big Biz Radio Show
Sunnyvale, CA –Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Monday, March 19, 2012 at 1:20 PM EDT. The live broadcast can be accessed via the show’s website: http://bigbizshow.com/media/ . Amarantus’ previous four appearances on the Big Biz Show and other CEO interviews are available for viewing online at http://www.amarantus.com/investor-relations/videos.html .
The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics and biomarkers surrounding the intellectual property and proprietary technologies it owns and has rights to for the treatment and diagnosis of Parkinson’s disease and other human diseases. The Company owns the intellectual property rights to an anti-apoptotic therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), and owns an inventory of 88 cell lines referred to as “PhenoGuard Cell Lines” from which MANF was discovered. The Company also has a license to the NuroPro™ diagnostic test for Parkinson’s disease from Power3 Medical Products. For further information please visit www.amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications, advantages presented by Amarantus’ PhenoGuard technology, and/or possible benefits of the NuroPro™ diagnostic platform, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Gerald E. Commissiong
408-737-2734 ext. 102
Investor Relations Contact: